



Consultations

Consultation on the draft 2022/23 Invitation to tender (Industry)

21 July 2022

Overview

Te Pātaka Whaioranga – Pharmac is seeking feedback from pharmaceutical suppliers, distributors, wholesalers, and other interested parties on the contents of the 2022/23 Invitation to Tender.

Consultation closes at 5 pm (New Zealand standard time) on Thursday 25 August 2022

Email feedback to tender@pharmac.govt.nz

We are seeking feedback on the draft 2022/23 tender. This is still under development and may change before it is taken to the Pharmac Board or its Delegate for approval and subsequently issued. In particular, we are seeking:

- feedback on the draft tender list and draft tender agreement
- commercial proposals as an alternative to including a product in the 2022/23 Invitation to Tender.

We are also seeking feedback from healthcare professionals and people who take medicines.

- [Healthcare professionals' consultation](#)
- [Patients' and public consultation](#)

Depending on the extent of any changes, Pharmac does not intend to send out further drafts for consultation at this stage.

[Suppliers' guide to Pharmac's annual tender process](#)

Key changes this tender

This year we have restructured and updated the terms within the invitation to tender document, due to the health sector reforms, to streamline the schedules, to have succinct

contract terms and to focus on the contractual relationship. The document will also be more consistent with our standard medicine listing agreement template, which is also being updated. Key points are as follows:

Structural Changes

- Schedules 4 – 6 have been combined into one schedule, as Schedule 4, which sets out the contract terms for both community and hospital supply.
- Schedule 7 is now Schedule 5, in the event any additional special terms are required for a pharmaceutical.

Health sector reform changes

- References to DHBs have been substituted with a reference to Te Whatu Ora.
- References to the New Zealand Public Health and Disability Act 2000 have been removed.

Contract terms

- Substantively the contract terms are similar to previous tenders.
- Terms included in previous tenders have been combined, reframed and redrafted to logically fit into sections for ease of reference.
- New reporting terms have been added, which set out the mechanism between the parties to manage supply issues.
- Additional terms have been added, for example to clarify the status of the Agreement in the event a pharmaceutical is delisted.

We will be hosting a supplier briefing session on Thursday 18 August 2022 to further discuss the changes to the Pharmac terms and conditions. Please submit any topics you would like covered and/or any questions you have by Thursday 11 August 2022 to tender@pharmac.govt.nz.

New products

This year's Invitation to Tender includes six line items that have not previously been included in the tender or other competitive process.

- Cyproterone acetate with ethinyloestradiol – Tab 2 mg with ethinyloestradiol 35 mcg
- Macrogol 3350 with sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid – powder for oral soln
- Metaraminol tartrate – Inj 0.5 mg per ml, 5 ml
- Metaraminol tartrate – Inj 0.5 mg per ml, 20 ml
- Metaraminol tartrate – Inj 1 mg per ml, 10 ml
- Triamcinolone acetonide – Inj 40 mg per ml, 1 ml preservative-free

Other changes

As we indicated last year, we are implementing stronger packaging preferences for medicines pack sizes and packaging types to support our focus on environmental sustainability. This year we have included such preferences for 33 products. Details are included alongside affected products in Appendix Two.

Key dates

Consultation on the 2022/23 Invitation to Tender (ITT)

21 July 2022 – Consultation begins

19 August 2022 – Any alternative commercial proposals (ACPs) due.

11 August 2022 – Deadline for submission of questions for supplier briefing session

18 August 2022 – Supplier briefing session

25 August 2022 – Consultation closes

August 2022 – Negotiations about ACPs begin

September 2022 – Tender Clinical Advisory Committee meets

September/October 2022 – Consultation on any ACPs begin

Release of the 2022/23 Invitation to Tender

November 2022 – Final Invitation to Tender (ITT) issued

December 2022 – ITT closes

January 2023 – Tender Clinical Advisory Committee meets

Unresolved tender bids

We intend to review any unresolved tender bids from the 2019/20 Invitation to Tender (ITT), 2020/21 ITT, and 2021/22 ITT prior to issuing the 2022/23 tender. See Appendix One below.

Consequential changes

Because the tender can result in substantial price reductions, it often means that savings made can be used to fund new medicines. However, these price reductions can also lead to changes to the tendered products.

When awarding a tender, we might choose to:

- add products to the 'stat' dispensing list, which allows for people to have their prescriptions filled all at once rather than in monthly lots
- remove or change any funding restrictions (for example, a Special Authority restriction, endorsement, or prescriber-type restriction), we might change or remove funding restrictions to enable more people to use it. Further consultation on this may occur later.

We are interested in your feedback on the clinical appropriateness of these potential changes. You can see the Pharmaceutical Schedule for all dispensing and funding restrictions: [schedule.pharmac.govt.nz/latest/Schedule.pdf](https://www.pharmac.govt.nz/latest/Schedule.pdf)

Alternative commercial proposals

Pharmac is open to any alternative commercial proposals (ACPs) to tendering that you may wish to submit. ACPs may involve offering savings:

- on one set of pharmaceuticals in return for Pharmac agreeing to defer tendering on another group of pharmaceuticals for a period
- by way of rebates rather than through price reductions.

The following points apply to ACPs for both the community and Te Whatu Ora - Health New Zealand hospital markets.

- ACPs should include at least one item listed in Schedule Two of the draft 2022/23 tender.
- ACPs may include more than one line item and may include pharmaceuticals not listed in Schedule Two of the draft 2022/23 tender.
- ACPs should not include any items subject to an unresolved tender.
- ACPs may seek Pharmac’s agreement to defer tendering or application of reference pricing for a period of time for any pharmaceutical, whether or not it is listed in Schedule Two of the draft 2022/23 tender.
- ACPs may not propose awarding Principal Supply Status in the community or Te Whatu Ora Hospitals, or any other form of sole or exclusive supply.
- Pharmac reserves the right:
 - not to accept any ACPs and/or
 - not to provide reasons for the acceptance or non-acceptance of any ACP and/or
 - to enter into an agreement or arrangement that differs in a material respect from that envisaged in this letter.

ACPs are due by **4 pm (New Zealand Time), Friday 19 August 2022**. Pharmac may not consider any ACPs that are submitted after this date.

Usage data for ‘PCT only’ injectable products

The table below contains ‘PCT only’ usage data for the year ended 30 June 2022 for items included in the 2022/23 tender. These volumes are approximate and indicative only. Pharmac makes no representation as to the accuracy of these figures or the level of sales or likely sales of any tender item.

Chemical	Total usage (mg)
Bleomycin Sulphate	15,163,103*
Cisplatin	325,294
Gemcitabine hydrochloride	8,924,633
Melphalan	71,550
Methotrexate	5,282,092
Paclitaxel	1,597,326
*Usage shown in IU (international units)	

Electronic tender (eTender) system

The 2022/23 tender will be distributed via Pharmac’s electronic tendering portal.

The portal requires companies to register for a user account. Details of how to register will be distributed before we release the final 2022/23 Invitation to Tender.

Please let us know if the contact details for the person responsible for submitting tender bids have changed for your company by emailing tender@pharmac.govt.nz

To provide feedback

Feedback should be provided to the tender analysts via email at tender@pharmac.govt.nz

All feedback received before the closing date will be considered by Pharmac's Board or its delegate prior to finalising the 2022/23 Invitation to Tender.

Your feedback may be shared

Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.

We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.

Appendix One – Unresolved tenders

2019/20 Invitation to Tender

Chemical Name	Line Item
Exemestane	Tab 25 mg
Docetaxel	Inj 80 mg
Ephedrine	Inj 3 mg per ml, 10 ml prefilled syringe
Exemestane	Tab 25 mg

Chemical Name	Line Item
Noradrenaline	Inj 0.06 mg per ml, 50 ml vial
Noradrenaline	Inj 0.1 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.12 mg per ml, 50 ml vial

2020/21 Invitation to Tender

Chemical Name	Line Item
Baclofen	Tab 10 mg
Brimonidine tartrate with timolol maleate	Eye drops 0.2% with timolol maleate 0.5%
Carboplatin	Inj 10 mg per ml, 45 ml
Chlorhexidine gluconate	Mouthwash 0.2%
Dapsone	Tab 100 mg
Ethambutol hydrochloride	Tab 400 mg
Felodipine	Tab long-acting 2.5 mg
Fenofibrate	Cap/tab 48 mg
Fenofibrate	Cap/tab 145 mg
Hydroxychloroquine sulphate	Tab 200 mg
Lanreotide	Inj 60 mg per 0.5 ml, 0.5 ml syringe
Lanreotide	Inj 90 mg per 0.5 ml, 0.5 ml syringe
Lanreotide	Inj 120 mg per 0.5 ml, 0.5 ml syringe
Methotrexate	Inj 7.5 mg prefilled syringe
Methotrexate	Inj 10 mg prefilled syringe
Methotrexate	Inj 15 mg prefilled syringe

Chemical Name	Line Item
Methotrexate	Inj 20 mg prefilled syringe
Methotrexate	Inj 25 mg prefilled syringe
Midodrine	Tab 2.5 mg
Midodrine	Tab 5 mg
Noradrenaline	Inj 0.06 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.1 mg per ml, 100 ml bag
Noradrenaline	Inj 0.12 mg per ml, 100 ml bag
Noradrenaline	Inj 0.16 mg per ml, 50 ml syringe
Oxaliplatin	Inj 100 mg
Prednisolone	Rectal foam 10-20%
Ramipril	Cap/tab 1.25 mg
Ramipril	Cap/tab 2.5 mg
Ramipril	Cap/tab 5 mg
Ramipril	Cap/tab 10 mg
Terlipressin	Inj 0.2 mg per ml, 5 ml
Terlipressin	Inj 1 mg per 8.5 ml ampoule
Vecuronium	Inj 10 mg

2021/22 Invitation to Tender

Chemical Name	Line Item
Acetazolamide	Tab 250 mg
Adrenaline autoinjector	Inj 0.15 mg er 0.3 ml
Adrenaline autoinjector	Inj 0.3 mg per 0.3 ml
Amisulpride	Tab 100 mg
Amisulpride	Tab 200 mg
Amisulpride	Tab 400 mg
Amoxicillin	Cap 250 mg
Amoxicillin	Cap 500 mg
Amoxicillin clavulanate	Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml
Amoxicillin clavulanate	Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml
Atomoxetine	Cap 10 mg
Atomoxetine	Cap 18 mg
Atomoxetine	Cap 25 mg
Atomoxetine	Cap 40 mg
Atomoxetine	Cap 60 mg
Atomoxetine	Cap 80 mg
Budesonide	Cap 3 mg controlled release
Capecitabine	Tab 150 mg
Capecitabine	Tab 500 mg
Ceftriaxone sodium	Inj 500 mg
Ceftriaxone sodium	Inj 1 g
Ceftriaxone sodium	Inj 2 g
Cetirizine hydrochloride	Tab 10 mg
Cetomacrogol with glycerol	Crn 90% with glycerol 10%, 500 ml
Cetomacrogol with glycerol	Crn 90% with glycerol 10, 1,000 ml
Cetomacrogol with glycerol	Crn 90% with glycerol 10%, 100 g
Chlortalidone [Chlothalidone]	Tab 25 mg

Chemical Name	Line Item
Clindamycin	Cap hydrochloride 150 mh
Clindamycin	Inj 150 mg per ml, 4 ml ampoule
Clobazam	Liq
Coal tar	Soln BP
Codeine phosphate	Tab 15 mg
Codeine phosphate	Tab 30 mg
Codeine phosphate	Tab 60 mg
Compound electrolytes with glucose [dextrose]	Soln with electrolytes
Compound hydroxybenzoate	Soln
Daptomycin	Inj 350 – 500 mg
Dexamfetamine sulfate	Tab 5 mg
Domperidone	Tab 10 mg
Enalapril	Tab 5 mg
Enalapril	Tab 10 mg
Enalapril	Tab 20 mg
Ertapenem	Inj 1 g vial
Ethinylestradiol with levonorgestrel	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tabs
Ethinylestradiol with levonorgestrel	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tabs
Fentanyl	Inj 10 mcg per ml, 100 ml premixed bag
Fluoxetine hydrochloride	Cap 20 mg
Fluoxetine hydrochloride	Tab dispersible 20 mg, scored
Glycerin with sodium saccharin	Suspension
Glycerin with sucrose	Suspension
Haloperidol	Inj 5 mg per ml, 1 ml
Hydrocortisone	Crn 1% (pack size greater than 100 g)
Levosimendan	Inj 2.5 mg per ml, 5 ml

Chemical Name	Line Item
Medroxyprogesterone acetate	Inj long-acting 150 mg per ml, 1 ml syringe
Methyl hydroxybenzoate	Powder
Methylcellulose	Powder
Methylcellulose with glycerin and sodium saccharin	Suspension
Nicorandil	Tab 10 mg
Nicorandil	Tab 20 mg
Nimodipine	Inj 0.2 mg per ml, 50 ml
Noradrenaline	Inj 1 mg per ml, 4 ml ampoule
Nortriptyline hydrochloride	Tab 10 mg
Nortriptyline hydrochloride	Tab 25 mg
Ondansetron	Tab 4 mg
Ondansetron	Tab 8 mg
Ondansetron hydrochloride	Inj 2 mg per ml, 2 ml
Ondansetron hydrochloride	Inj 2 mg per ml, 4 ml
Oxybutynin	Tab 5 mg
Pantoprazole	Tab EC 20 mg
Pantoprazole	Tab EC 40 mg
Pemetrexed	Inj 100 mg
Pemetrexed	Inj 500 mg
Permethrin	Crn 5%
Pethidine hydrochloride	Tab 50 mg
Phenobarbitone	Tab 15 mg
Phenobarbitone	Tab 30 mg
Piperacillin with tazobactam	Inj 4 mg with tazobactam 500 mg
Posaconazole	Oral liq 40 mg per ml
Posaconazole	Tab modified-release 100 mg

Chemical Name	Line Item
Progesterone (current access)	Cap 100 mg
Progesterone (widened access)	Cap 100 mg
Pyridostigmine bromide	Tab 60 mg
Risedronate sodium	Tab 35 mg
Risperidone	Inj 25 mg
Risperidone	Inj 37.5 mg
Risperidone	Inj 50 mg
Sertraline	Tab 50 mg
Sertraline	Tab 100 mg
Sodium bicarbonate	Powder BP
Sodium hyaluronate [hyaluronic acid]	Inj 30 mg per ml
Sumatriptan	Inj 12 mg per ml, 0.5 ml
Syrup (pharmaceutical grad)	Liq
Tenecteplase	Inj 50 mg
Teriparatide (current access)	Inj 250 mcg per ml
Teriparatide (widened access)	Inj 250 mcg per ml
Thiotepa	Inj 15 mg
Thiotepa	Inj 100 mg
Tranlycypromine sulphate	Tab 10 mg
Trientine	Tab 150 mg
Trientine	Tab 250 – 300 mg
Vinorelbine	Cap 20 mg
Vinorelbine	Cap 30 mg
Vinorelbine	Cap 80 mg
Voriconazole	Inj 200 mg vial
Water for injection	Purified for inj, 10 ml
Zinc and castor oil	Oint (pack size greater than or equal to 500 g)
Zinc and castor oil	Oint (pack size 50 g or less)

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Acitretin					
Cap 10 mg	520,425	\$154,915	\$0.2977	C H 5%	Preference for a blister pack.
Cap 25 mg	104,703	\$72,175	\$0.6893	C H 5%	Preference for a blister pack.
Alfentanil					
Inj 0.5 mg per ml, 2 ml ampoule				H 5%	
Allopurinol					
Tab 100 mg	28,298,623	\$649,170	\$0.0229	C H 5%	Preference for a scored tablet.
Tab 300 mg	21,118,812	\$1,206,729	\$0.0571	C H 5%	Preference for a scored tablet.
Ambrisentan					
Tab 10 mg	11,650	\$601,917	\$51.6667	C H 5%	Longer transition period may apply to this product.
Tab 5 mg	4,056	\$209,560	\$51.6667	C H 5%	Longer transition period may apply to this product.
Amitriptyline					
Tab 10 mg	25,181,446	\$627,018	\$0.0249	C H 5%	Preference for a scored and/or dispersible tablet.
Tab 25 mg	8,159,364	\$123,206	\$0.0151	C H 5%	
Tab 50 mg	3,073,595	\$77,147	\$0.0251	C H 5%	
Amlodipine					
Tab 2.5 mg	14,097,368	\$169,168	\$0.0120	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 5 mg	25,695,696	\$274,173	\$0.0107	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 10 mg	13,591,221	\$179,676	\$0.0132	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Amorolfine					
Nail soln 5%	148,135	\$442,331	\$2.9860	C H 5%	
Amoxicillin					
Grans for oral liq 125 mg per 5 ml	5,626,189	\$78,767	\$0.0140	C H 5%	Preference for products which include a measuring device.
Grans for oral liq 250 mg per 5 ml	32,477,430	\$561,860	\$0.0173	C H 5%	Preference for products which include a measuring device.
Amoxicillin clavulanate					
Tab amoxicillin 500 mg with potassium clavulanate 125 mg	10,325,281	\$918,950	\$0.0890	@ C H 5%	
Anastrozole					
Tab 1 mg	668,016	\$101,318	\$0.1517	C H 5%	
Aspirin					
Tab 100 mg EC	88,360,404	\$963,932	\$0.0109	C H 5%	
Tab dispersible or soluble 300 mg	781,454	\$35,165	\$0.0450	C H 5%	
Atracurium Besylate					
Inj 10 mg per ml, 2.5 ml				H 5%	
Inj 10 mg per ml, 5 ml				H 5%	
Atropine sulphate					
Eye drops 1%	116,010	\$134,262	\$1.1573	C H 5%	
Azithromycin					
Tab 250 mg	60,420	\$16,495	\$0.2730	C H 5%	
Bendroflumethiazide [Bendrofluazide]					
Tab 2.5 mg	17,533,816	\$701,353	\$0.0400	C H 5%	
Tab 5 mg	2,645,959	\$182,836	\$0.0691	C H 5%	
Benzatropine Mesylate					
Inj 1 mg per ml, 2 ml ampoule	1,002	\$19,038	\$19.0000	C H 5%	
Benzylnicillin sodium [Penicillin G]					
Inj 600 mg	5,526	\$6,128	\$1.1090	C H 5%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Betahistine dihydrochloride					
<u>Tab 16 mg</u>	4,130,294	\$190,820	\$0.0462	C H 5%	
Betamethasone Dipropionate					
<u>Crn 0.05% (pack size greater than 30 g)</u>	386,770	\$278,474	\$0.7200	C H 5%	
<u>Oint 0.05% (pack size greater than 30 g)</u>	421,840	\$303,725	\$0.7200	C H 5%	
Bicalutamide					
<u>Tab 50 mg</u>	695,680	\$104,602	\$0.1504	C H 5%	
Bisoprolol Fumarate					
Tab 2.5 mg	13,286,711	\$271,580	\$0.0204	C H 5%	Preference for a scored tablet, and for a pack size of 30 or 90 tablets in a bottle pack.
Tab 5 mg	7,057,743	\$199,946	\$0.0283	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 10 mg	2,412,029	\$97,012	\$0.0402	C H 5%	Preference for a pack ize of 30 or 90 tablets in a bottle pack.
Bleomycin Sulphate					
Inj 15,000 iu vial				PCT H 5%	
Bupivacaine hydrochloride					
Inj 2.5 mg per ml, 20 ml ampoule				H 5%	
Inj 2.5 mg per ml, 100 ml bag				H 5%	
Inj 5 mg per ml, 4 ml				H 5%	
Bupropion hydrochloride					
<u>Tab modified-release 150 mg</u>	3,184,267	\$1,167,575	\$0.3667	C H 5%	
Calcium carbonate					
<u>Tab</u>	8,008,658	\$214,312	\$0.0268	C H 5%	Preference for tab 1.25 g - 1.5 g.
Capsaicin					
<u>Crn 0.025%</u>	2,535,075	\$549,266	\$0.2167	C H 5%	
Capsaicin (current access)					
<u>Crn 0.075%</u>	505,329	\$134,215	\$0.2656	C H 5%	Current restrictions may apply. Pharmac would only award a tender for either current or widened access. Widened access would be a listing on the Schedule without restrictions.
Capsaicin (widened access)					
Crn 0.075%				C H 5%	Pharmac would only award a tender for either current or widened access. Widened access would be a listing on the Schedule without restrictions.
Cefazolin sodium					
Inj 2 g				C H 5%	Not currently listed on the Pharmaceutical Schedule.
<u>Inj 500 mg</u>	340	\$231	\$0.6780	C H 5%	
<u>Inj 1 g</u>	20,197	\$14,098	\$0.6980	C H 5%	
Cefotaxime					
Inj 1 g				H 5%	
Ceftazidime					
Inj 1 g				H 5%	
Cefuroxime sodium					
Inj 750 mg				H 5%	
Inj 1.5 g				H 5%	
Ciprofloxacin					
<u>Tab 250 mg</u>	138,119	\$11,938	\$0.0864	C H 5%	Preference for a scored, dispersible tablet.
<u>Tab 500 mg</u>	769,202	\$93,404	\$0.1214	C H 5%	Preference for a scored, dispersible tablet.
<u>Tab 750 mg</u>	32,175	\$6,837	\$0.2125	C H 5%	Preference for a scored, dispersible tablet.
Cisplatin					
Inj 1 mg per ml, 50 ml				PCT H 5%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Clarithromycin					
Inj 500 mg				H 5%	
Clonidine					
<u>TDDS 2.5 mg, 100 mcg per day</u>	66,540	\$172,006	\$2.5850	C H 5%	
<u>TDDS 5 mg, 200 mcg per day</u>	29,123	\$95,960	\$3.2950	C H 5%	
<u>TDDS 7.5 mg, 300 mcg per day</u>	18,479	\$78,212	\$4.2325	C H 5%	
Colecalciferol					
<u>Cap/Tab 1.25 mg</u>	3,571,101	\$877,884	\$0.2458	C H 5%	
Colistin Sulphomethate					
Inj 150 mg	5,874	\$381,810	\$65.0000	C H 5%	
Cyproterone acetate with ethinyloestradiol					
Tab 2 mg with ethinyloestradiol 35 mcg				C H 5%	Not currently listed in the Pharmaceutical Schedule. Pharmac would consider bids for products not containing inert tablets. Pharmac reserves the right to award a single tender for the entire cyproterone with ethinyloestradiol market.
<u>Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets</u>	9,479,568	\$280,974	\$0.0296	C H 5%	Pharmac reserves the right to award a single tender for the entire cyproterone with ethinyloestradiol market.
Darunavir					
Tab 400 mg	81,856	\$180,083	\$2.2000	C H 5%	Preference for a dispersible tablet.
Tab 600 mg	26,184	\$85,818	\$3.2775	C H 5%	Preference for a dispersible tablet.
Desmopressin					
<u>Nasal spray 10 mcg per dose</u>	88,284	\$411,256	\$4.6583	C H 5%	
Dexmedetomidine hydrochloride					
Inj 100 mcg per ml, 2 ml vial				H 5%	
Diazepam					
<u>Tab 2 mg</u>	2,924,149	\$357,156	\$0.1221	C H 5%	Preference for a scored tablet.
<u>Tab 5 mg</u>	4,394,023	\$646,800	\$0.1472	C H 5%	
Docusate Sodium					
<u>Tab 50 mg</u>	884,724	\$20,437	\$0.0231	C H 5%	
<u>Tab 120 mg</u>	1,536,799	\$48,102	\$0.0313	C H 5%	
Donepezil hydrochloride					
<u>Tab 5 mg</u>	1,347,891	\$64,995	\$0.0482	C H 5%	
<u>Tab 10 mg</u>	1,184,480	\$87,391	\$0.0738	C H 5%	
Emulsifying ointment					
Oint BP (pack size of 200 g or less)				H 5%	
Oint BP (pack size greater than 200 g)	32,574,394	\$221,506	\$0.0068	C H 5%	
Ephedrine					
Inj 30 mg per ml, 1ml				H 5%	
Escitalopram					
<u>Tab 10 mg</u>	15,105,621	\$577,186	\$0.0382	C H 5%	Preference for a scored tablet.
<u>Tab 20 mg</u>	5,208,199	\$357,126	\$0.0686	C H 5%	
Ezetimibe					
<u>Tab 10 mg</u>	8,228,171	\$534,831	\$0.0650	C H 5%	
Febuxostat					
<u>Tab 120 mg</u>	169,333	\$120,955	\$0.7143	C H 5%	
<u>Tab 80 mg</u>	676,395	\$483,142	\$0.7143	C H 5%	
Fibre supplement					
<u>Powder/granules</u>	73,638,250	\$1,796,773	\$0.0244	C H 5%	Units and unit subsidy shown as per the 500 g presentation currently listed and expressed as 'per g'. Preference for a product containing psyllium husk.

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name				Unit Subsidy	ABA Limit	Comments
Line Item	Units	Cost				
Finasteride						
<u>Tab 5 mg</u>	5,811,630	\$279,539	\$0.0481		C H 5%	Preference for a blister pack.
Flecainide Acetate						
Cap long-acting 100 mg	1,109,011	\$486,856	\$0.4390		C H 5%	Longer transition timeframes may apply.
Cap long-acting 200 mg	1,112,332	\$754,655	\$0.6784		C H 5%	Longer transition timeframes may apply.
Inj 10 mg per ml, 15 ml	51	\$1,020	\$20.0000		C H 5%	
Tab 50 mg	419,485	\$139,479	\$0.3325		C H 5%	Longer transition timeframes may apply.
Flucloxacillin sodium						
<u>Inj 1 g</u>	6,161	\$7,024	\$1.1400		C H 5%	
Fluconazole						
<u>Cap 50 mg</u>	181,884	\$17,863	\$0.0982		C H 5%	
<u>Cap 150 mg</u>	134,034	\$87,122	\$0.6500		C H 5%	
<u>Cap 200 mg</u>	80,333	\$36,982	\$0.4604		C H 5%	
Fosfomycin (current access)						
Powder					H 5%	
Fosfomycin (widened access)						
Powder					C H 5%	Not currently listed in Section B. Special Authority criteria may apply. No proposed changes to Section H restrictions.
Ganciclovir						
Inj 500 mg vial					H 5%	
Gemcitabine hydrochloride						
<u>Inj 1 g</u>					PCT H 5%	
Gliclazide						
<u>Tab 80 mg</u>	21,095,238	\$640,451	\$0.0304		C H 5%	
Glucagon Hydrochloride						
<u>Inj 1 mg syringe kit</u>	21,406	\$684,992	\$32.0000		C H 5%	Preference for a graduated and/or prefilled syringe.
Glucose [Dextrose]						
<u>Inj 50%, 10 ml - 20 ml</u>	12,511	\$76,692	\$6.1300		C H 5%	Inj 50%, 10 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 10 ml ampoule.
<u>Inj 50%, 90 ml - 100 ml</u>	476	\$7,140	\$15.0000		C H 5%	Inj 50%, 90 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 90 ml ampoule.
Solution 15 g					H 5%	
Glyceryl trinitrate						
Inj 1 mg per ml, 10 ml					H 5%	
Goserelin						
Implant 10.8 mg, syringe	26,907	\$3,292,610	\$122.3700		C H 5%	Refer to Schedule 5 for additional Special Terms.
Implant 3.6 mg, syringe	11,410	\$749,435	\$65.6800		C H 5%	Refer to Schedule 5 for additional Special Terms.
Granisetron						
Inj 1 mg per ml					H 5%	
Hydrocortisone with wool fat and mineral oil						
<u>Lotn 1% with wool fat hydrous 3% and mineral oil</u>	10,570,725	\$446,930	\$0.0423		C H 5%	Preference for a pack size of 300 g or less.
Hydroxyurea						
Cap 500 mg	1,353,460	\$322,394	\$0.2382		PCT C H 5%	
Hyoscine N-butylbromide						
<u>Inj 20 mg, 1 ml</u>	179,634	\$228,135	\$1.2700		C H 5%	
<u>Tab 10 mg</u>	5,761,864	\$365,878	\$0.0635		C H 5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name			Unit			
Line Item	Units	Cost	Subsidy	ABA Limit	Comments	
Imatinib mesilate						
Cap 400 mg	102,421	\$289,476	\$2.8263	C H 5%	Pharmac reserves the right to award a tender for all indications. Additional implementation support may be required to support a brand change. Usage figures are for non-GIST market only.	
Cap 100 mg	155,738	\$151,144	\$0.9705	C H 5%	Pharmac reserves the right to award a tender for all indications. Additional implementation support may be required to support a brand change. Usage figures are for non-GIST market only.	
Indapamide						
Tab 2.5 mg	2,035,333	\$236,323	\$0.1161	C H 5%		
Iodine supplement						
Tab 150 mcg elemental	11,892,079	\$605,188	\$0.0509	C H 5%		
Isosorbide mononitrate						
Tab 20 mg	580,607	\$113,509	\$0.1955	C H 5%		
Tab long-acting 40 mg	636,991	\$174,109	\$0.2733	C H 5%		
Tab long-acting 60 mg	6,410,771	\$658,899	\$0.1028	C H 5%		
Ketoconazole						
Shampoo 2%	6,451,100	\$208,371	\$0.0323	C H 5%		
Lamivudine						
Tab 100 mg	78,239	\$19,420	\$0.2482	C H 5%		
Tab 150 mg	148,170	\$208,672	\$1.4083	C H 5%		
Latanoprost with timolol						
Eye drops 0.005% with timolol 0.5%	46,630	\$23,222	\$0.4980	C H 5%		
Leflunomide						
Tab 10 mg	616,953	\$123,391	\$0.2000	C H 5%	Preference for a scored tablet.	
Tab 20 mg	798,875	\$159,775	\$0.2000	C H 5%		
Levodopa with Carbidopa						
Tab 100 mg with carbidopa 25 mg	9,913,017	\$2,092,638	\$0.2111	C H 5%	Longer transition periods may apply to this product.	
Tab 250 mg with carbidopa 25 mg	347,736	\$133,496	\$0.3839	C H 5%	Longer transition periods may apply to this product.	
Tab long-acting 200 mg with carbidopa 50 mg	1,836,240	\$801,519	\$0.4365	C H 5%	Longer transition periods may apply to this product. Pharmacokinetic data required.	
Levonorgestrel						
Subdermal implant	12,179	\$1,302,179	\$106.9200	C H 5%	Longer transition periods may apply to this product. Training should be provided to clinicians if awarded. Refer to Schedule 5 for additional Special Terms.	
Losartan						
Tab 12.5 mg	5,909,927	\$109,747	\$0.0186	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.	
Tab 25 mg	9,210,090	\$201,701	\$0.0219	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.	
Tab 50 mg	12,457,774	\$333,744	\$0.0268	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.	
Tab 100 mg	7,638,854	\$318,311	\$0.0417	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.	
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride						
Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	10,381,124	\$2,318,416	\$0.2233	C H 5%		
Macrogol 3350 with sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid						
Powder for oral soln				H 5%	Not currently listed in the Pharmaceutical Schedule.	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name			Unit			
Line Item	Units	Cost	Subsidy	ABA Limit	Comments	
Magnesium sulphate						
<u>Inj 2 mmol per ml, 5ml</u>	21,967	\$56,082	\$2.5530	C H 5%		
Mebeverine hydrochloride						
<u>Tab 135 mg</u>	2,754,493	\$281,564	\$0.1022	C H 5%		
Melphalan						
<u>Inj 50 mg vial</u>				PCT H 1%		
Meropenem						
<u>Inj 500 mg</u>				H 5%		
<u>Inj 1 g</u>				H 5%		
Metaraminol tartrate						
<u>Inj 0.5 mg per ml, 10 ml</u>				H 5%		
<u>Inj 0.5 mg per ml, 20 ml</u>				H 5%		
<u>Inj 0.5 mg per ml, 5 ml</u>						
<u>Inj 1 mg per ml, 1 ml</u>				H 5%		
<u>Inj 1 mg per ml, 10 ml</u>				H 5%		
<u>Inj 10 mg per ml, 1 ml</u>				H 5%		
Methotrexate						
<u>Inj 100 mg per ml, 50 ml</u>		\$65,805	\$79.9900	PCT C H 5%	Preference for products where stability data >48 hours post-compounding.	
Methylprednisolone aceponate						
<u>Crm 0.1%</u>	549,540	\$163,395	\$0.2973	C H 5%		
<u>Oint 0.1%</u>	362,580	\$107,806	\$0.2973	C H 5%		
Metoclopramide hydrochloride						
<u>Tab 10 mg</u>	5,736,378	\$74,573	\$0.0130	C H 5%		
Metronidazole						
<u>Inj 5 mg per ml, 100 ml</u>				H 5%	Preference for a bag presentation with space to add another antibiotic.	
<u>Tab 200 mg</u>	362,003	\$48,002	\$0.1326	C H 5%	Preference for a scored, dispersible tablet.	
<u>Tab 400 mg</u>	2,112,363	\$526,084	\$0.2491	C H 5%		
Metyrapone						
<u>Cap 250 mg</u>	29,585	\$330,169	\$11.1600	C 5%		
Miconazole nitrate						
<u>Crm 2% (15 g - 20 g pack)</u>	2,796,060	\$150,987	\$0.0540	C H 5%		
<u>Vaginal crm 2% with applicator</u>	452,760	\$77,988	\$0.1723	C H 5%	Single use applicators preferred.	
Morphine						
<u>Inj 1 mg per ml, 10 ml syringe</u>				H 5%	Morphine sulphate inj 1 mg per ml, 10 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.	
<u>Inj 1 mg per ml, 100 ml bag</u>				H 5%	Morphine sulphate inj 1 mg per ml, 100 ml bag is currently listed in Section H of the Pharmaceutical Schedule.	
<u>Inj 1 mg per ml, 50 ml syringe</u>				H 5%	Morphine sulphate inj 1 mg per ml, 50 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.	
<u>Tab immediate-release 10 mg</u>	3,759,493	\$1,052,658	\$0.2800	C H 5%	Preference for blister packs. Units and subsidy shown are for morphine sulphate tab immediate-release 10 mg.	
<u>Tab immediate-release 20 mg</u>	632,388	\$349,078	\$0.5520	C H 5%	Preference for blister packs. Units and subsidy shown are for morphine sulphate tab immediate-release 20 mg.	
Moxifloxacin						
<u>Tab 400 mg</u>	17,981	\$151,040	\$8.4000	C H 5%		
Naltrexone hydrochloride						
<u>Tab 50 mg</u>	264,115	\$1,173,812	\$4.4443	C H 5%		
Nystatin						
<u>Oral liq 100,000 u per ml</u>	1,728,984	\$126,786	\$0.0733	C H 5%		

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Nystatin					
<u>Vaginal crm 100,000 u per 5 g with applicator(s)</u>	144,750	\$7,720	\$0.0533	C H 5%	Units and unit subsidy expressed as 'per g'.
Oestriol					
<u>Crm 1 mg per g with applicator(s)</u>	3,622,485	\$1,598,711	\$0.4413	C H 5%	Applicator(s) should be multiple use and a measured dose.
<u>Pessaries 500 mcg</u>	417,780	\$191,063	\$0.4573	C H 5%	
<u>Tab 2 mg</u>	166,032	\$38,735	\$0.2333	C H 5%	Preference for tablets to be scored.
Olanzapine					
<u>Orodispersible tab 5 mg</u>	392,548	\$25,374	\$0.0646	C H 5%	
<u>Orodispersible tab 10 mg</u>	537,702	\$45,705	\$0.0850	C H 5%	
<u>Tab 2.5 mg</u>	2,129,083	\$102,643	\$0.0482	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 5 mg</u>	2,691,178	\$151,863	\$0.0564	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 10 mg</u>	2,961,970	\$212,640	\$0.0718	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Omeprazole					
<u>Cap 10 mg</u>	7,963,375	\$171,690	\$0.0216	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack.
<u>Cap 20 mg</u>	110,835,038	\$2,290,960	\$0.0207	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack.
<u>Cap 40 mg</u>	31,917,260	\$1,103,060	\$0.0346	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack.
Ondansetron					
<u>Tab disp 4 mg</u>	2,986,569	\$226,979	\$0.0760	C H 5%	
<u>Tab disp 8 mg</u>	1,234,570	\$139,506	\$0.1130	C H 5%	
Paclitaxel					
Inj 100 mg				PCT H 5%	Preference for products where stability data >48 hours post-compounding.
Inj 300 mg				PCT H 5%	Preference for products where stability data >48 hours post-compounding.
Paracetamol					
Suppos 125 mg	108,084	\$38,802	\$0.3590	C H 5%	
Inj 10 mg per ml, 100 ml				H 5%	
Suppos 250 mg	60,840	\$25,431	\$0.4180	C H 5%	
Suppos 500 mg	121,489	\$30,129	\$0.2480	C H 5%	
Paraffin					
White soft (pack size 2000 g or more)	2,071,299	\$16,562	\$0.0080	C 5%	Only funded in combination.
White soft (pack size 500 g or less)	128,146	\$1,421	\$0.0111	C H 5%	
Permethrin					
<u>Lotion 5%</u>	1,209,090	\$160,809	\$0.1330	C H 5%	
Pimecrolimus					
<u>Crm 1%</u>	52,530	\$99,807	\$1.9000	C H 5%	
Pine tar with triethanolamine lauryl sulphate and fluorescein					
<u>Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium</u>	21,626,777	\$192,046	\$0.0089	C H 5%	
Poloxamer					
<u>Oral drops 10%</u>	275,430	\$36,541	\$0.1327	C H 5%	
Povidone Iodine					
Oint 10%	941,901	\$107,188	\$0.1138	C H 5%	
Pravastatin					
Tab 20 mg	3,822,866	\$288,091	\$0.0754	C H 5%	
Tab 40 mg	2,073,130	\$267,289	\$0.1289	C H 5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Prednisolone					
Rectal Foam 10 - 20%	1,204	\$6,373	\$5.2929	C H 5%	Pharmac reserves the right to award a tender to one steroidal rectal product for the whole market.
Prochlorperazine					
<u>Tab 5 mg</u>	3,449,692	\$110,390	\$0.0320	C H 5%	
Pyridoxine hydrochloride					
<u>Tab 25 mg</u>	1,157,966	\$34,739	\$0.0300	C H 5%	
Quetiapine					
<u>Tab 100 mg</u>	4,138,527	\$232,668	\$0.0562	C H 5%	Preference for a pack size of 30 or 90 tablets in a blister pack.
<u>Tab 200 mg</u>	1,192,165	\$117,893	\$0.0989	C H 5%	Preference for a pack size of 30 or 90 tablets in a blister pack.
<u>Tab 25 mg</u>	28,110,192	\$671,552	\$0.0239	C H 5%	Preference for a scored tablet, and for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 300 mg</u>	486,185	\$69,471	\$0.1429	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Remifentanil hydrochloride					
Inj 1 mg				H 5%	
Inj 2 mg				H 5%	
Rifampicin					
<u>Cap 150 mg</u>	67,362	\$39,434	\$0.5854	C H 5%	
<u>Cap 300 mg</u>	177,112	\$216,183	\$1.2206	C H 5%	
Inj 600 mg				H 5%	
<u>Oral liq 100 mg per 5 ml</u>	74,501	\$15,645	\$0.2100	C H 5%	
Rifaximin					
<u>Tab 200 mg - 550 mg</u>	177,640	\$1,982,588	\$11.1607	C H 5%	Tab 550 mg is currently listed on the Pharmaceutical Schedule. Units shown are for tab 550 mg.
Risperidone					
<u>Oral liquid 1 mg per ml</u>	436,001	\$129,348	\$0.2967	C H 5%	
<u>Tab 0.5 mg</u>	3,374,198	\$104,600	\$0.0310	C H 5%	Preference for a pack size of 60 or 180 tablets in a bottle pack.
<u>Tab 1 mg</u>	2,167,617	\$74,414	\$0.0343	C H 5%	Preference for a pack size of 60 or 180 tablets in a bottle pack.
<u>Tab 2 mg</u>	1,007,412	\$38,453	\$0.0382	C H 5%	Preference for a pack size of 60 or 180 tablets in a bottle pack.
<u>Tab 3 mg</u>	426,586	\$17,776	\$0.0417	C H 5%	Preference for a pack size of 60 or 180 tablets in a bottle pack.
<u>Tab 4 mg</u>	187,866	\$10,708	\$0.0570	C H 5%	Preference for a pack size of 60 or 180 tablets in a bottle pack.
Rizatriptan					
<u>Tab orodispersible 10 mg</u>	2,235,118	\$271,947	\$0.1217	C H 5%	
Ropivacaine hydrochloride					
Inj 2 mg per ml, 10 ml ampoule				H 5%	
Inj 2 mg per ml, 20 ml				H 5%	
Inj 2 mg per ml, 100 ml				H 5%	
Inj 2 mg per ml, 200 ml				H 5%	
Inj 7.5 mg per ml, 10 ml				H 5%	
Inj 7.5 mg per ml, 20 ml				H 5%	
Inj 10 mg per ml, 10 ml				H 5%	
Inj 10 mg per ml, 20 ml				H 5%	
Rosuvastatin					
<u>Tab 5 mg</u>	210,363	\$11,921	\$0.0567	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 10 mg</u>	371,573	\$29,974	\$0.0807	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Rosuvastatin					
<u>Tab 20 mg</u>	420,277	\$54,916	\$0.1307	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 40 mg</u>	337,648	\$59,426	\$0.1760	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Roxithromycin					
Tab 150 mg	1,312,868	\$217,411	\$0.1656 @	C H 5%	Additional Stock Pharmaceutical
Tab 300 mg	635,051	\$207,408	\$0.3266 @	C H 5%	Additional Stock Pharmaceutical
Simvastatin					
<u>Tab 10 mg</u>	3,075,595	\$42,043	\$0.0137	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 20 mg</u>	13,253,968	\$299,010	\$0.0226	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 40 mg</u>	11,383,998	\$452,855	\$0.0398	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 80 mg</u>	772,532	\$61,115	\$0.0791	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Sodium Citro-Tartrate					
<u>Grans effervescent 4 g sachets</u>	2,335,205	\$185,158	\$0.0793	C H 5%	
Suxamethonium chloride					
Inj 50 mg per ml, 2 ml				H 5%	
Tacrolimus					
<u>Oint 0.1%</u>	62,190	\$68,409	\$1.1000	C H 5%	
Tamoxifen citrate					
<u>Tab 10 mg</u>	44,665	\$11,166	\$0.2500	C H 5%	
<u>Tab 20 mg</u>	1,766,310	\$195,760	\$0.1108	C H 5%	
Temazepam					
<u>Tab 10 mg</u>	2,621,249	\$139,450	\$0.0532	C H 5%	Preference for a scored tablet.
Terbinafine					
<u>Tab 250 mg</u>	2,026,389	\$196,600	\$0.0970	C H 5%	
Teriflunomide					
<u>Tab 14 mg</u>	14,196	\$334,569	\$23.5679	C H 5%	
Timolol					
Eye drops 0.5%, gel forming	55,038	\$83,217	\$1.5120	C H 5%	For products containing BAK, Pharmac reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml
Timolol maleate					
<u>Eye drops 0.25%</u>	212,790	\$77,030	\$0.3620	C H 5%	For products containing BAK, Pharmac reserves the right to list a BAK or preservative free product for a restricted market. Please note that this line item is for non gel-forming drops.
<u>Eye drops 0.5%</u>	145,920	\$59,535	\$0.4080	C H 5%	For products containing BAK, Pharmac reserves the right to list a BAK or preservative free product for a restricted market. Please note that this line item is for non gel-forming drops.
Tobramycin					
<u>Solution for inhalation 60 mg per ml, 5 ml</u>	15,015	\$105,909	\$7.0536	C H 5%	
Tramadol hydrochloride					
<u>Cap 50 mg</u>	31,652,770	\$886,278	\$0.0280	C H 5%	
Inj 50 mg per ml, 1 ml ampoule				H 5%	
Inj 50 mg per ml, 2 ml ampoule				H 5%	
<u>Tab sustained-release 100 mg</u>	5,186,631	\$394,184	\$0.0760	C H 5%	
<u>Tab sustained-release 150 mg</u>	480,172	\$50,418	\$0.1050	C H 5%	
<u>Tab sustained-release 200 mg</u>	355,869	\$48,932	\$0.1375	C H 5%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Triamcinolone acetonide					
<u>0.1% in Dental Paste USP</u>	127,930	\$136,373	\$1.0660	C H 5%	
<u>Inj 10 mg per ml, 1 ml</u>	4,352	\$18,104	\$4.1600	C H 5%	Pharmac reserves the right to list a preservative free product in addition to this product for the ophthalmic market.
Inj 10 mg per ml, 1 ml preservative-free				C H 5%	Not currently listed in the Pharmaceutical Schedule. Restrictions may apply.
<u>Inj 40 mg per ml, 1 ml</u>	71,614	\$731,895	\$10.2200	C H 5%	Pharmac reserves the right to list a preservative free product in addition to this product for the ophthalmic market.
Inj 40 mg per ml, 1 ml preservative-free				C H 5%	Not currently listed in the Pharmaceutical Schedule. Restrictions may apply.
<u>Crm 0.02%</u>	3,294,400	\$207,547	\$0.0630	C H 5%	
<u>Oint 0.02%</u>	1,887,600	\$119,863	\$0.0635	C H 5%	
Ursodeoxycholic acid					
<u>Cap 250 mg - 300 mg</u>	1,096,709	\$361,366	\$0.3295	C H 5%	Cap 250 mg is currently listed on the Pharmaceutical Schedule. Units shown are for cap 250 mg.
Vancomycin hydrochloride					
<u>Inj 500 mg</u>	7,653	\$17,985	\$2.3500	C H 5%	